Basilea Pharmaceutica launches phase 3 trial for antifungal drug fosmanogepix in candidemia and invasive candidiasis.

Basilea Pharmaceutica has launched a phase 3 clinical trial for its antifungal drug, fosmanogepix, aimed at treating adult patients with candidemia and invasive candidiasis, serious infections caused by Candida yeast. Fosmanogepix, which has received multiple FDA designations, is evaluated against standard treatment caspofungin in a global, randomized, double-blind study. This trial seeks to establish its efficacy and safety as a first-in-class treatment.

September 24, 2024
4 Articles